Pharma has to find new growth pills as Covid booster wears off
Synopsis
The pandemic provided a reason to the stock market to be excited about the pharma sector that had been facing lacklustre prospects amid challenges in the US business, USFDA compliance issues, pricing pressure, big-bang acquisitions not working out on expected lines and modest growth in the domestic market.
ET Intelligence Group: With the weekly pandemic death toll reaching the lowest worldwide last week since March 2020, the World Health Organization has indicated the end of Covid-19 may be in sight.
However, going by the performance of the pharma sector on the bourses, the pandemic probably ended much before for the sector – a standout straggler on the stock market through the ‘reopening’ trade.
The ET Pharma Index is down 14% even as the
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Why ?
-
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
-
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
-
Clean experience with
Minimal Ads -
Comment & Engage with ET Prime community -
Exclusive invites to Virtual Events with Industry Leaders -
A trusted team of Journalists & Analysts who can best filter signal from noise
For all the latest Business News Click Here
For the latest news and updates, follow us on Google News.